JP2011507879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507879A5 JP2011507879A5 JP2010539763A JP2010539763A JP2011507879A5 JP 2011507879 A5 JP2011507879 A5 JP 2011507879A5 JP 2010539763 A JP2010539763 A JP 2010539763A JP 2010539763 A JP2010539763 A JP 2010539763A JP 2011507879 A5 JP2011507879 A5 JP 2011507879A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- compound according
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 22
- 239000000651 prodrug Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000003380 propellant Substances 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- -1 anti-infectives Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 108010059108 CD18 Antigens Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 208000000592 Nasal Polyps Diseases 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 2
- 206010068318 Oropharyngeal discomfort Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 108010016672 Syk Kinase Chemical class 0.000 claims description 2
- 102000000551 Syk Kinase Human genes 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 239000002617 bone density conservation agent Substances 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 229940124581 decongestants Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229940066493 expectorants Drugs 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 2
- 0 C*OC(c1ccccc1)OS Chemical compound C*OC(c1ccccc1)OS 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1614407P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/087301 WO2009085880A2 (en) | 2007-12-21 | 2008-12-18 | C-21 thioethers as glucocorticoid receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507879A JP2011507879A (ja) | 2011-03-10 |
| JP2011507879A5 true JP2011507879A5 (OSRAM) | 2012-02-02 |
Family
ID=40513892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539763A Pending JP2011507879A (ja) | 2007-12-21 | 2008-12-18 | グルココルチコイド受容体アゴニストとしてのｃ−２１チオエーテル |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110262368A1 (OSRAM) |
| EP (1) | EP2235035A2 (OSRAM) |
| JP (1) | JP2011507879A (OSRAM) |
| CN (1) | CN102099368A (OSRAM) |
| AR (1) | AR070040A1 (OSRAM) |
| CA (1) | CA2710240A1 (OSRAM) |
| CL (1) | CL2008003802A1 (OSRAM) |
| MX (1) | MX2010007024A (OSRAM) |
| PE (1) | PE20091215A1 (OSRAM) |
| TW (1) | TW200940070A (OSRAM) |
| WO (1) | WO2009085880A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091525A1 (es) | 2007-12-21 | 2009-09-25 | Schering Corp | Agonista del receptor glucocorticoide c-20-c21 sustituido |
| UY32520A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |
| CN103694306B (zh) * | 2014-01-07 | 2016-03-23 | 成都医路康医学技术服务有限公司 | 一种布地奈德s异构体制备r异构体的方法 |
| RS62040B1 (sr) | 2016-06-02 | 2021-07-30 | Abbvie Inc | Agonist receptora glukokortikoida i njegovi imunokonjugati |
| KR20250114431A (ko) * | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| CN110944718A (zh) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | 环糊精蛋白质药物偶联物 |
| CA3080857A1 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| EP3658192B1 (en) | 2017-12-01 | 2021-04-28 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| JP7366028B2 (ja) | 2018-01-08 | 2023-10-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ステロイド及びその抗体コンジュゲート |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| CN120344545A (zh) * | 2022-12-16 | 2025-07-18 | 津药生物科技（天津）有限公司 | 新型糖皮质激素、其制备方法及用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2231374B1 (OSRAM) * | 1973-05-30 | 1976-10-22 | Jouveinal Sa | |
| FR2510582B1 (fr) * | 1981-07-30 | 1986-05-30 | Sipsy | Steroides esterifies en la position 17 et thio-esterifies en la position 21, leur procede de preparation et leur application comme medicament |
| FR2551069B1 (fr) * | 1983-08-26 | 1986-07-25 | Jouveinal Sa | 17-oxo-21-thioesters d'hydrocortisone, leur preparation et leurs applications comme medicament |
| US5223493A (en) * | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| US6013244A (en) * | 1995-12-29 | 2000-01-11 | Glaxo Wellcome Inc. | 21-(2-oxo-tetrahydrofuran)-thio pregnane derivatives, a process for their production and pharmaceutical compositions containing them |
| US20100209508A1 (en) * | 2005-06-14 | 2010-08-19 | Corus Pharma, Inc. | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction |
| PE20091525A1 (es) * | 2007-12-21 | 2009-09-25 | Schering Corp | Agonista del receptor glucocorticoide c-20-c21 sustituido |
-
2008
- 2008-12-18 CN CN2008801273009A patent/CN102099368A/zh active Pending
- 2008-12-18 EP EP08866275A patent/EP2235035A2/en not_active Withdrawn
- 2008-12-18 TW TW097149503A patent/TW200940070A/zh unknown
- 2008-12-18 PE PE2008002135A patent/PE20091215A1/es not_active Application Discontinuation
- 2008-12-18 WO PCT/US2008/087301 patent/WO2009085880A2/en not_active Ceased
- 2008-12-18 US US12/736,064 patent/US20110262368A1/en not_active Abandoned
- 2008-12-18 JP JP2010539763A patent/JP2011507879A/ja active Pending
- 2008-12-18 MX MX2010007024A patent/MX2010007024A/es not_active Application Discontinuation
- 2008-12-18 AR ARP080105526A patent/AR070040A1/es not_active Application Discontinuation
- 2008-12-18 CL CL2008003802A patent/CL2008003802A1/es unknown
- 2008-12-18 CA CA2710240A patent/CA2710240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507879A5 (OSRAM) | ||
| JP2011507878A5 (OSRAM) | ||
| AU2008286027B2 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| EP2447253B1 (en) | Dihydropyrimidine compounds, preparation methods, pharmaceutical compositions thereof and their use as antiviral agents | |
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| JP2009514954A5 (OSRAM) | ||
| US8729073B2 (en) | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | |
| US10611729B2 (en) | Farnesoid X receptor antagonists | |
| JP2017526716A5 (OSRAM) | ||
| DE602004006627T2 (de) | Nicotinamid-derivate, die verwendbar sind als pde4-inhibitoren | |
| JP2007518767A5 (OSRAM) | ||
| JP2009514910A (ja) | 肺高血圧を処置するためのジアリールウレア | |
| CN115697988A (zh) | 3,4-二氢异喹啉类化合物及其应用 | |
| EP3562306A2 (en) | Metalloenzyme inhibitor compounds | |
| CN115916345B (zh) | 吡咯并吡啶衍生物及其用途 | |
| US20120213867A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| US6403589B1 (en) | Method of treating pain with draflazine-analogues | |
| WO2005100341A1 (ja) | ２－アミノピリミジン誘導体 | |
| CN106714798B (zh) | 血脂异常症治疗剂 | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| RU2006126828A (ru) | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза | |
| JP2008247878A (ja) | イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物 | |
| EP1757593A1 (en) | Therapeutic agent for nonviral hepatitis | |
| CN107286147B (zh) | N-[5-(1,2,4-三唑-1-基)噻唑-2-基]吗啉基酰胺及其医药用途 | |
| US20110039848A1 (en) | Five-membered ring compound |